Clinical Trial Update: A Phase 2a Study to Evaluate EDP-938 in the Virus Challenge Model [Phase 2]

View source ↗

Summary

Phase 2a study evaluating EDP-938 in an RSV infection virus challenge model has been completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• EDP-938 (EDP-938)

Snippet

Sponsor: Enanta Pharmaceuticals, Inc | Conditions: RSV Infection | Phase 2 | Status: COMPLETED | Results posted: 2022-05-03